RxDoctor Payments Data

Allan Bernstein

Neurology · Sebastopol, CANPI 1992889067

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Biogen accounts for 91.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $1,769 and has fallen 96.5% since, to $63 in 2025.

$3,403in general payments, 2019–2025

Across 12 payments — averaging $283.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$3K
  • Lilly USA, LLC$131
  • Eisai Inc.$49
  • Impel Pharmaceuticals Inc.$36
  • Eli Lilly$28
  • Amgen$26
  • plus $25 from 1 others
$2,575,542in research payments, 2019–2025

Across 55 payments — averaging $46,828 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1.4M
  • Novartis$524K
  • Biogen$329K
  • Eisai Inc.$288K
  • Genentech, Inc.$81K

What the payments were for

  • Consulting fees$1,41342%
  • Speaking & faculty fees$1,69550%
  • Food & beverage$2959%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,403 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Other neurology in Sebastopol

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →